Topics

Valo licenses oncolytic virus technology from University of Helsinki

14:40 EST 13 Feb 2020 | Elsevier Business Intelligence

Valo Therapeutics Ltd. licensed the PeptiENV oncolytic virus technology from the University of Helsinki. The platform allows ...

Original Article: Valo licenses oncolytic virus technology from University of Helsinki

NEXT ARTICLE

More From BioPortfolio on "Valo licenses oncolytic virus technology from University of Helsinki"

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...